BNTC · Benitec Biopharma Inc.
AI read · Good for BNTC
The AI's read
The findings offer an early sign that BB-301 could help with swallowing problems, and no serious events were reported. The evidence covers 9 patients, so it does not yet show whether the results will hold in the key trial. That trial is planned to start in mid-2027. The fiscal-year change only shifts how the company groups its reports.